Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Trevi Therapeutics, Inc. TRVI

Healthcare  —  Biotechnology
14.41 (0.27) (1.84%) as of 25 Sep
Market cap
$2.1B
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Trevi Therapeutics, Inc. (TRVI) Business Profile

Updated before January 2025

Company Overview

Trevi Therapeutics, Inc. (TRVI) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious neurologically mediated conditions. Founded in 2011 and headquartered in New Haven, Connecticut, Trevi Therapeutics focuses on addressing unmet medical needs in areas where current treatment options are limited or non-existent. The company was co-founded by Jennifer L. Good, who serves as the President and Chief Executive Officer, and Thomas Sciascia, M.D., who is the Chief Medical Officer. Under their leadership, Trevi has built a strong foundation in research and development, with a focus on leveraging its expertise in the central and peripheral nervous systems.

The company’s flagship product candidate, Haduvio™ (nalbuphine ER), is being developed for the treatment of chronic pruritus (itching) and other conditions mediated by the central nervous system. Trevi’s commitment to innovation and patient-centric solutions has positioned it as a key player in the biopharmaceutical industry.

Core Business Segments

Trevi Therapeutics operates primarily in the biopharmaceutical sector, with a focus on developing therapies for neurologically mediated conditions. The company’s core business segments include:

1. Neurologically Mediated Conditions

Trevi’s primary focus is on developing treatments for conditions that are mediated by the central and peripheral nervous systems. These include:

  • Chronic Pruritus: Haduvio™ (nalbuphine ER) is being developed as a treatment for chronic pruritus associated with prurigo nodularis, a condition characterized by severe itching and skin lesions. This is a significant unmet medical need, as current treatment options are limited.
  • Cough Associated with Idiopathic Pulmonary Fibrosis (IPF): Trevi is also exploring the potential of Haduvio™ to address chronic cough in patients with IPF, a progressive and fatal lung disease.

2. Research and Development

Trevi invests heavily in R&D to expand its pipeline of innovative therapies. The company’s research efforts are focused on understanding the underlying mechanisms of neurologically mediated conditions and developing targeted treatments.

Business Model

Trevi Therapeutics operates on a business model centered around innovation, clinical development, and strategic partnerships. The key components of its business model include:

  • Product Development: Trevi focuses on developing therapies that address unmet medical needs. The company’s flagship product candidate, Haduvio™, is a testament to its commitment to innovation.
  • Clinical Trials: Trevi conducts rigorous clinical trials to ensure the safety and efficacy of its products. The company collaborates with leading research institutions and healthcare providers to advance its clinical programs.
  • Revenue Generation: While Trevi is currently in the clinical-stage and does not yet generate revenue from product sales, its long-term revenue model is based on the successful commercialization of its therapies.
  • Strategic Partnerships: Trevi collaborates with academic institutions, research organizations, and industry partners to accelerate the development and commercialization of its therapies.

Strategic Direction

Trevi Therapeutics has a clear strategic vision for the future, which includes:

  • Advancing Haduvio™: The company is focused on advancing the clinical development of Haduvio™ for chronic pruritus and chronic cough associated with IPF. Trevi aims to secure regulatory approvals and bring this innovative therapy to market.
  • Expanding the Pipeline: Trevi is committed to expanding its pipeline of therapies for neurologically mediated conditions. The company is exploring new indications and therapeutic areas where its expertise can make a difference.
  • Sustainability Goals: Trevi is dedicated to operating in an environmentally and socially responsible manner. The company is exploring ways to minimize its environmental footprint and contribute to the well-being of the communities it serves.
  • Global Expansion: Trevi aims to expand its presence in international markets, leveraging strategic partnerships and collaborations to reach a broader patient population.

Competitive Landscape

Trevi Therapeutics operates in a competitive biopharmaceutical landscape, where it faces competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Regeneron Pharmaceuticals: Known for its innovative therapies, Regeneron is a major player in the biopharmaceutical industry.
  • Pfizer: A global leader in pharmaceuticals, Pfizer has a strong presence in the treatment of neurologically mediated conditions.
  • Biogen: Specializing in neurological disorders, Biogen is a significant competitor in Trevi’s target market.
  • Emerging Biotech Firms: Smaller biotech companies developing therapies for chronic pruritus and other neurologically mediated conditions also pose competition.

Trevi differentiates itself through its focus on unmet medical needs and its innovative approach to drug development.

Risk Factors

Like any biopharmaceutical company, Trevi Therapeutics faces several risks, including:

  • Regulatory Risks: The approval process for new therapies is complex and uncertain. Delays or rejections by regulatory authorities could impact Trevi’s ability to bring its products to market.
  • Market Dependence: Trevi’s success is heavily dependent on the commercialization of Haduvio™. Failure to achieve market acceptance could affect the company’s financial performance.
  • Supply Chain Disruptions: Disruptions in the supply chain for raw materials and manufacturing could delay the development and commercialization of Trevi’s therapies.
  • Competition: Intense competition from established pharmaceutical companies and emerging biotech firms could impact Trevi’s market share.
  • Financial Risks: As a clinical-stage company, Trevi relies on external funding to finance its operations. Limited financial resources could constrain its ability to execute its strategic plans.

Recent Developments

Trevi Therapeutics has made significant progress in recent years, including:

  • Clinical Trials: The company has advanced the clinical development of Haduvio™, with promising results from Phase 2 trials for chronic pruritus and chronic cough associated with IPF.
  • Regulatory Milestones: Trevi has engaged with regulatory authorities to discuss the path to approval for Haduvio™.
  • Corporate Strategies: The company has strengthened its leadership team and expanded its research capabilities to support its growth objectives.
  • Global Developments: The COVID-19 pandemic posed challenges for clinical trials and supply chains, but Trevi adapted by implementing remote monitoring and other innovative solutions.

Investment Considerations

Investors considering Trevi Therapeutics should weigh the following factors:

Strengths

  • Innovative Pipeline: Trevi’s focus on unmet medical needs and its innovative approach to drug development are key strengths.
  • Experienced Leadership: The company’s leadership team has a proven track record in the biopharmaceutical industry.
  • Market Potential: The target markets for Haduvio™ represent significant revenue opportunities.

Risks

  • Clinical and Regulatory Risks: The success of Trevi’s pipeline depends on the outcomes of clinical trials and regulatory approvals.
  • Financial Uncertainty: As a clinical-stage company, Trevi relies on external funding, which may not always be available.
  • Competitive Pressure: Intense competition from established players and emerging biotech firms could impact Trevi’s market position.

Conclusion

Trevi Therapeutics, Inc. is a promising clinical-stage biopharmaceutical company with a focus on addressing unmet medical needs in neurologically mediated conditions. With its innovative pipeline, experienced leadership, and commitment to patient-centric solutions, Trevi is well-positioned for future growth. However, investors should carefully consider the risks associated with clinical-stage companies, including regulatory and financial uncertainties. As Trevi advances its pipeline and explores new opportunities, it has the potential to make a significant impact in the biopharmaceutical industry.